Strategic Growth NCM-USA aims to become a top distributor of radiopharmaceuticals for Molecular Imaging and Targeted Radionuclide Therapy within 3-5 years, signaling a potential near-term ramp in demand for related services, logistics, and regulatory support that sales teams can align with.

Expanded Manufacturing The facility has been redesigned to support therapeutic radiopharmaceutical production in addition to PET radiopharmaceuticals, indicating opportunities to cross-sell Manufacturing Services, GMP compliance, and quality control capabilities to pharma partners pursuing diversified radiopharmaceutical portfolios.

ClinicalTrial Support NCM-USA supports IND-led clinical trials for diagnostic and therapeutic studies, presenting openings for CRO partnerships, lab services, radiopharmacy staffing, and supply chain solutions tailored to trial timelines and regulatory requirements.

Scale and Capabilities With two GE cyclotrons, multiple automated synthesis modules, hot cells, and a robust QC lab, NCM-USA offers high-throughput radiopharmaceutical production that could benefit suppliers of raw materials, automation software, and analytical instrumentation.

Competitive Differentiation The ability to manufacture multiple radiopharmaceuticals simultaneously by an experienced chemist and radiopharmacist team positions NCM-USA as a reliable partner for customers seeking flexible, scalable, and compliant radiopharmaceutical manufacturing and distribution solutions.